Meet Cerenetex
We’re Revolutionizing the Diagnosis of Large Vessel Occlusion (LVO) Ischemic Strokes.
The Problem:
Strokes affect 15 million people worldwide and are a leading cause of disability and death in the world. The delay in current stroke treatment leads to incorrect diagnosis and poses a significant challenge to timely triage.
Our Mission:
Cerenetex is leading the charge to objectively diagnose Large Vessel Occlusion (LVO) ischemic strokes to minimize the delay-in-care and injury to the brain.
The Solution:
By creating a technology that seamlessly integrates with subjective neurological tests, we can enhance the accuracy of patient triaging and accelerate the path to treatment for patients who have experienced an LVO stroke.
Cerenetex is at the forefront of revolutionizing the diagnosis of Large Vessel Occlusion (LVO) ischemic strokes, with a mission to reduce delays in care and brain injury.
Strokes Affect 15 Million Individuals Globally Every Year
Addressing the current delay in stroke treatment is critical as it often results in misdiagnosis and hinders prompt triage.
